AGM Information • May 2, 2017
AGM Information
Open in ViewerOpens in native device viewer
Press release, May 2, 2017
Today, on May 2, 2017, an annual shareholders' meeting was held in Alligator Bioscience AB. A summary of the resolutions adopted follows below. All resolutions were adopted with necessary majority.
The annual shareholders' meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and the consolidated balance sheet. The annual shareholders' meeting also resolved to distribute the company's result in accordance with the proposal from the board meaning that no dividends are paid and that the available funds of SEK 642,667,275 are carried forward to a new account.
The annual shareholders' meeting resolved to discharge the members of the board and the CEO from liability for the financial year 2016.
The annual shareholders' meeting resolved, in accordance with the proposal from the Nomination Committee, to re-elect Peter Benson, Carl Borrebaeck, Kenth Petersson, Jonas Sjögren and Ulrika Danielsson as ordinary board members and to elect Anders Ekblom as new ordinary board member. Peter Benson was re-elected as Chairman of the board.
Furthermore, the annual shareholders' meeting resolved that the total remuneration to the board and its Committees shall be paid with a maximum of SEK 1,675,000, of which SEK 400,000 shall be paid to the Chairman of the board and of which SEK 225,000 shall be paid to each of the other board members who are not employed by the company. Remuneration for committee work shall be paid with SEK 100,000 to the Chairman of the Audit Committee and SEK 25,000 shall be paid to each of the other members in the Audit Committee. No remuneration shall be paid for committee work in the Remuneration Committee.
The annual shareholders' meeting also resolved to re-elect Ernst & Young AB as the auditor and that the remuneration for the auditor shall be paid in accordance with customary norms and approved invoice. Ernst & Young AB has informed that Johan Thuresson will be appointed as the responsible auditor.
The annual shareholders' meeting resolved that a Nomination Committee shall be appointed before the coming election and remuneration. The Nomination Committee shall consist of four members, representing the three largest shareholders at the last weekday of September, together with the Chairman of the board. Furthermore, an instruction and charter for the Nomination Committee was adopted.
The annual shareholders' meeting resolved in accordance with the proposal from the board to adopt a Remuneration Policy regarding determination of remuneration and other benefits for the CEO and other senior executives.
Lund on May 2, 2017 Alligator Bioscience AB (publ)
Per Norlén, CEO Telephone: + 46 46 286 42 80 (switchboard) E-mail: [email protected]
Rein Piir, VP Investor Relations at Alligator Telephone: +46 708 537292 E-mail: [email protected]
Per-Olof Schrewelius, CFO Telephone: +46 46 286 42 85 E-mail: [email protected]
The information in the press release was submitted for publication, through the agency of the contact persons set out above, at 7 p.m. CET on 2 May, 2017.
Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was outlicensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company's shares are listed on Nasdaq Stockholm under the ticker "ATORX". The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit www.alligatorbioscience.com.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.